Chart, page-5193

A down market on the ASX of over 1.5%. The bio tech sector came through relatively unscathed. This is a change from what we have seen over the past dew months. To early to call a change of sentiment or bottom, but a positive change all the same.

Some interesting news also published about competitive gene therapy drugs. With the drug manufactures admitting the problems seem to relate to all the gene therapy class of drugs. This is hugely positive news for ATL 1102. We seem to be trading along a base, admittedly on low volume. So a kick @rse price sensitive announcement now may just be what we need.

Maybe time for the ANP bugle to be blown to differentiate it from the gene therapies and draw some market attention to where we are at. Empathizing previous results and safety, and shining a huge spot light of the pending approval trial. Its terrible to kick competitors when they are down, but drawing attention now to how our combination trial may be the savior to these other treatments may also be needed to be yelled from high places. The timing now may be as good as it gets.